| Autor: |
Lucijanic, M., Jurin, I., Jurin, H., Starcevic, B., Skelin, M., Glasnovic, A., Hadzibegovic, I. |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| DOI: |
10.1097/01.hs9.0000559572.74207.d4 |
| Popis: |
Background Advent of direct/non-vitamin-K- dependent anticoagulants (DOAC/NOAC) has dramatically changed the practice of anticoagulation. Due to fixed dosing of direct oral anticoagulants (DOACs) and high lipophilicity, uncertainty exists about their efficacy/safety in a population of obese/overweight patients. Aims We aimed to investigate in the real-life setting whether DOAC anticoagulated patients with atrial fibrillation stratified according to the different BMI subgroups experience different risks of unwanted outcomes. Methods We retrospectively investigated a real-life cohort of 325 anticoagulated patients with atrial fibrillation who started anticoagulation in our institution in period 2011- 2018. Patients received predominantly dabigatran [179/325 (55%)], followed by apixaban [74/325 (23%)] and rivaroxaban [72/325 (22%)]. Clinical data were obtained from the hospital information system. Patients were stratified according to the body mass index (BMI) subgroups: non-obese with BMI |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
